Guangji Pharmaceutical disclosed a performance forecast on July 14. It is estimated that the net profit loss for the first half year of 2026 will be 51 million yuan to 66 million yuan, and a loss of 75.515 million yuan for the same period last year, a year-on-year decrease of losses. During the reporting period, the overall market environment of the industry did not improve significantly. The company continued to optimize refined internal operation management, and steadily promoted work related to cost reduction and efficiency, achieving a significant decrease in expenses during the current period compared to the same period last year; at the same time, the company's income from disposal of idle assets increased year-on-year in the current period.

Guangji Pharmaceutical disclosed a performance forecast on July 14. It is estimated that the net profit loss for the first half year of 2026 will be 51 million yuan to 66 million yuan, and a loss of 75.515 million yuan for the same period last year, a year-on-year decrease of losses. During the reporting period, the overall market environment of the industry did not improve significantly. The company continued to optimize refined internal operation management, and steadily promoted work related to cost reduction and efficiency, achieving a significant decrease in expenses during the current period compared to the same period last year; at the same time, the company's income from disposal of idle assets increased year-on-year in the current period.